A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkx307PMID 28922809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

  2017cited by this paper
• The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent

  2017cited by this paper
• Linezolid as treatment for pulmonary Mycobacterium avium disease

  2017cited by this paper
• A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting

  2017cited by this paper
• Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease

  2017cited by this paper
• Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

  2017cited by this paper
• Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

  2016cited by this paper
• Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

  2016cited by this paper
• A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

  2016cited by this paper
• Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

  2015cited by this paper
• Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

  2014cited by this paper
• Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

  2012cited by this paper
• The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

  2012cited by this paper
• Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

  2010cited by this paper
• Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

  2010cited by this paper
• Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit.

  2008cited by this paper
• An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

  2007cited by this paper
• Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

  2007cited by this paper
• Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

  2007cited by this paper
• Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.

  2006cited by this paper
• Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.

  2001cited by this paper
• Oxazolidinones Mechanism of Action: Inhibition of the First Peptide Bond Formation*

  2001cited by this paper
• Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients.

  1998cited by this paper
• Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.

  1996cited by this paper
• Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus.

  1996cited by this paper
• Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.

  1995cited by this paper
• Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.

  1994cited by this paper
• Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease

  1994cited by this paper
• Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

  1994cited by this paper
• An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers

  1991cited by this paper

• Pharmacodynamic evidence for tedizolid use in Mycobacterium avium lung disease

  2026cites this paper
• Buruli ulcer

  2025cites this paper
• Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations

  2025cites this paper
• Antibacterial action of penicillin against Mycobacterium avium complex

  2024influential citation
• Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fiber model.

  2024cites this paper
• Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients

  2023cites this paper
• Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses

  2022cites this paper
• Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

  2021cites this paper
• New therapies for nontuberculous mycobacterial lung infection

  2021cites this paper
• Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fiber system that simulates human plasma and epithelial lining fluid pharmacokinetics.

  2021cites this paper
• Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

  2021cites this paper
• Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System

  2021cites this paper
• Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

  2020cites this paper
• Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii

  2020cites this paper
• New β-Lactam–β-Lactamase Inhibitor Combinations

  2020cites this paper
• Slow-Growing Nontuberculous Mycobacteria in Transplant

  2020cites this paper
• Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria

  2019influential citation
• Nontuberculous mycobacteria in solid organ transplant.

  2019cites this paper
• Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

  2019cites this paper
• Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

  2019cites this paper
• Drug‐Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis

  2018cites this paper
• Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance

  2017cites this paper
• A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

  2017cites this paper
• A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting

  2017cites this paper
• Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

  2017cites this paper
• Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease

  2017cites this paper
• Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis

  2017cites this paper
• Treatment of Mycobacterium avium-intracellulare complex: a great leap forward.

  2017cites this paper
• Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates

  2017cites this paper